Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
02/2005
02/15/2005US6855510 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
02/15/2005US6855509 Measurement of protein s activity in sample; obtain sample, monitor clotting time, compare to control, evaluate protein s activity
02/15/2005US6855497 Detecting spinocerebellar ataxia; obtain tissue sample, incubate with probe, hybridization of probe indicates spinocerebellar ataxia
02/15/2005US6855496 Detection of preferential nucleic acid ligands; obtain nucleotide sequences, incubate with oligonucleotides, hybridize, amplify, recover nucleotide sequences
02/15/2005US6855494 Method for increasing viability and transformation efficiency of bacteria during storage at low temperatures
02/15/2005US6855323 Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A
02/15/2005US6855322 A highly purified protein, Plasmodium falciparum MSP-142, which retains folding and disulfide bridging of the native molecule and is useful as a diagnostic reagent, antibody production, and as a vaccine for malaria
02/15/2005US6855321 Polyepitope carrier protein
02/15/2005US6855320 Fusing to the antigen a non-hemolytic truncated form of listeriolysin O.
02/15/2005US6855319 Gene encoding merozoite protein of Babesia caballi, recombinant protein obtained therefrom and utilization thereof
02/15/2005US6855318 Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
02/15/2005US6855317 Immunological herpes simplex virus antigens and methods for use thereof
02/15/2005US6855316 Combination of an adjuvant and an isolated p42 polypeptide comprising at least a portion of the 42 kDa C-terminal processing fragment of major merozoite surface protein gp195 from a Plasmodium falciparum isolate
02/15/2005US6855308 Anticancer, antitumor agents
02/15/2005US6854731 Method and device for playing an improved game of blackjack
02/10/2005WO2005012910A1 A peptide antigen
02/10/2005WO2005012904A1 Compositions and methods for monitoring breast cancer treatment
02/10/2005WO2005012902A1 Method of screening useful protein
02/10/2005WO2005012606A2 Concentrated aqueous silk fibroin solution and use thereof
02/10/2005WO2005012545A2 Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
02/10/2005WO2005012538A2 Accelerated vaccination
02/10/2005WO2005012536A1 Method of efficiently constructing growth regulatory recombinant adenovirus vector and kit for the construction thereof
02/10/2005WO2005012535A2 Method for producing life attenuated viruses and use of viral particles thus produced.
02/10/2005WO2005012532A1 System for the production of dimeric proteins based on the transport system of hemolysin of escherichia coli
02/10/2005WO2005012531A2 Antibody cdr polypeptide sequences with restricted diversity
02/10/2005WO2005012530A2 Antagonists and agonists of ldcam and methods of use
02/10/2005WO2005012527A1 Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
02/10/2005WO2005012526A1 Lafora's disease gene
02/10/2005WO2005012520A1 Gene imparting redifferentiation ability of plant and utilization of the same
02/10/2005WO2005012517A2 Use of the fret phenomenon for in vivo follow-up of biological events
02/10/2005WO2005012516A2 Maize cellulose synthases and uses thereof
02/10/2005WO2005012512A1 Scaffold-free self-organized 3d synthetic tissue
02/10/2005WO2005012498A2 Production of porphyrins
02/10/2005WO2005012492A2 Human skin equivalents expressing exogenous polypeptides
02/10/2005WO2005012491A2 Surface expression of biologically active proteins in bacteria
02/10/2005WO2005012489A2 Targeting endothelium for tissue-specific delivery of agents
02/10/2005WO2005012481A2 Non-immunoglobulin binding polypeptides
02/10/2005WO2005012363A1 Targeting inflammation inducer
02/10/2005WO2005012360A2 Binding molecules against sars-coronavirus and uses thereof
02/10/2005WO2005012359A2 Anti-vegf antibodies
02/10/2005WO2005012357A1 Bcl-2 splicing variants
02/10/2005WO2005012356A2 Gelatin capsules
02/10/2005WO2005012355A1 Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis
02/10/2005WO2005012353A1 Crystalline tumor necrosis factor receptor 2 polypeptides
02/10/2005WO2005012352A1 SOLUBLE HUMAN INTERLEUKIN 18 RECEPTOR-α, METHOD OF ASSAYING THE SAME, ASSAY KIT AND MEDICINAL COMPOSITION
02/10/2005WO2005012351A2 Novel functions for decay accelerating factor (daf) in inflammation
02/10/2005WO2005012350A2 Epha2 t-cell epitope agonists and uses therefor
02/10/2005WO2005012349A2 Chromatographic process for the purification of notch ligands
02/10/2005WO2005012348A2 Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells
02/10/2005WO2005012346A1 Long lasting insulin derivatives and methods thereof
02/10/2005WO2005012345A1 Perfusion method for producing erythropoietin
02/10/2005WO2005012344A1 Adipocyte complement related protein zacrp11
02/10/2005WO2005012343A1 Babesia vaccines
02/10/2005WO2005012342A1 Process for preparation of flax protein isolate
02/10/2005WO2005012341A2 Pichia methanolica secretory signal
02/10/2005WO2005012340A1 Nematicidal proteins
02/10/2005WO2005012339A2 Immunogenic protein and uses thereof
02/10/2005WO2005012338A1 Antigenic peptides of sars coronavirus and uses thereof
02/10/2005WO2005012337A2 Antigenic peptides of sars coronavirus and uses thereof
02/10/2005WO2005012336A2 Uranium-chelating peptides and uses thereof
02/10/2005WO2005012330A2 AMYLOID β-PEPTIDE AND METHODS OF USE
02/10/2005WO2005011742A1 Method of treating hepatocellular carcinoma
02/10/2005WO2005011733A1 Hybrid toxins comprising shiga-like toxin subunits fused to escherichia coli heat labile enterotoxin subunits and vaccines thereof
02/10/2005WO2005011732A2 Rabbit bacterium and uses thereof
02/10/2005WO2005011724A1 A method of producing an anticoagulation effect
02/10/2005WO2005011722A2 Use of vegf-c or vegf-d in reconstructive surgery
02/10/2005WO2005011607A2 Treatment of cancers expressing p95 erbb2
02/10/2005WO2005011584A2 Decorin proteoglycan inhibitor of fibrinogen blood clotting
02/10/2005WO2005011571A2 Hepatitis virus core proteins as vaccine platforms and methods of use thereof
02/10/2005WO2005011367A1 A chloroplast transgenic approach to express and purify human serum albumin, a protein highly susceptible to proteolytic degradation
02/10/2005WO2004111249A3 Protein constructs containing caspase recognition sites
02/10/2005WO2004111088A3 Angiogenic factor and inhibitors thereof
02/10/2005WO2004111081A3 Antigenic peptides of sars coronavirus and uses thereof
02/10/2005WO2004107618A3 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
02/10/2005WO2004097421A3 Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
02/10/2005WO2004094462A3 Methods of peptide preparation
02/10/2005WO2004093903A3 Methods and compositions for immunomodulation using cd1 antigens
02/10/2005WO2004092397A3 Tmprss2 regulatory sequences and uses thereof
02/10/2005WO2004087755A3 Plant haemoglobin
02/10/2005WO2004083807A3 Methods of evaluating glycomolecules for enhanced activities
02/10/2005WO2004078112A3 Apoptosis inducing gene
02/10/2005WO2004069865A3 Control of plant growth and developmental processes
02/10/2005WO2004058188A3 Vaccine compositions and methods
02/10/2005WO2004057941A3 RECESSIVE PLANT VIRAL RESISTANCE RESULTS FROM MUTATIONS IN TRANSLATION INITIATION FACTOR eIF4E
02/10/2005WO2004056960A3 Gene-coding polynucleotides of the chromosome of the bacterium chromobacterium violaceum, expression and activity of these polynucleotides and their applications
02/10/2005WO2004054907A3 Ftsz-polypeptides as a target for herbicidal compounds
02/10/2005WO2004043332A3 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
02/10/2005WO2004035774A3 Expression vectors for selection from stem cells of differentiated cardiomyocytes
02/10/2005WO2004024863A3 Adenoviral va1 pol iii expression system for rna expression
02/10/2005WO2004024068A3 Novel composition and methods for the treatment of immune related diseases
02/10/2005WO2004020589A3 The gene for a dof transcription factor capable of altering the size and stature of a plant
02/10/2005WO2004016647A3 Fragments of proinsulin c-peptide
02/10/2005WO2004003207A9 Production of peptides and proteins by accumulation in plant endoplasmic reticulum-derived protein bodies
02/10/2005WO2003086175A8 Compositions and methods for the therapy and diagnosis of lung cancer
02/10/2005WO2003083079A9 Bone generation by gene therapy
02/10/2005WO2003072731A3 STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
02/10/2005WO2003072723A3 Intracellular signaling molecules
02/10/2005WO2003068943A3 Secreted proteins
02/10/2005WO2003063760A3 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
02/10/2005WO2003060065A3 Adapter-directed display system